2021-10-28-深交所-中_关_村_2021年第三季度报告_14页_536kb

Financial Performance Overview: Beijing Zhongguancun Technology Co. Ltd. 2021 Q3 Report

The company reported a significant net loss for the third quarter of 2021, totaling 65.2 million yuan, representing a sharp decline of 729.85% compared to the same period in 2020. For the year-to-date, the net loss attributable to shareholders was 50 million yuan, down 322.29% year-over-year. Revenue for the quarter was 509.3 million yuan, up 6.33%, while YTD revenue reached 1.46 billion yuan, increasing by 17.44%. The company also showed positive operating cash flow of 135 million yuan for the YTD period, indicating improved cash management despite the net loss. The unaudited report highlights various operational challenges, including debt repayments and restructuring efforts.

Key Financial Data Changes

Several major financial items showed significant changes driven by corporate activities:

• Cash decreased by 45.79% due to repayments of short-term loans, affecting overall liquidity.
• Accounts receivable declined as some companies fulfilled payments, showing better collection efficiency.
• Research and development expenses rose by 89.88% due to increased spending by subsidiaries, supporting innovation but contributing to higher costs.
• Debt reductions were evident, with long-term borrowings down 33%, reflecting risk management.
• Shareholder equity saw a slight decrease of 2.94% YTD, while total assets fell 3.06%, indicating efforts to optimize capital structure.

Shareholder and Corporate Governance Information

The top shareholders remained dominated by Gree Group (27.78% stake) and Gree Electronics (7.37%), with significant minority investments from entities like a healthcare-themed fund. Shareholder changes included margin calls and additional stock pledges, totaling over 59% of shares pledged. The report compliantly declared that all financial data is accurate and free from material misstatements.

Important Company Events

Key developments included the conclusion of legal matters involving the CEO, who was released from detention, and ongoing stock control actions. The company adapted its strategy to focus on innovative pharmaceutical segments, aiming to build integrated production capabilities. Other highlights involved subsidiary successes, such as pharmaceutical approvals (e.g., saltacid tramadol passing consistency evaluation), and international certifications (e.g., CNAS accreditation for a lab), which could enhance market competitiveness.

Financial Statement Summary

The unaudited quarterly report provided detailed financial metrics: Revenue 1.46 billion yuan YTD, net loss 49.96 million yuan YTD. Operating cash flow was strong at 135 million yuan, supporting day-to-day operations. Strategic shifts towards R&D and new product clusters are expected to influence future performance, but current losses suggest continued financial strain. Overall, the company prioritized debt reduction and operational adjustments amid challenging market conditions.